liraglutide-depot (Novo Nordisk)

Liraglutide-depot (NN9023) is an investigational, long-acting formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide, developed by Novo Nordisk. It is designed as a sustained-release (depot) injection to extend the therapeutic window and potentially reduce dosing frequency compared to the standard once-daily liraglutide (Victoza). The drug functions by activating the GLP-1 receptor, which enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon secretion, and slows gastric emptying. These mechanisms collectively improve glycemic control in patients with type 2 diabetes mellitus. As of the provided context, it has been evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics in healthy subjects and patients with type 2 diabetes.

Other names

liraglutide depotsustained-release liraglutide